Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07652658 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
A Phase 2 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 359
- Enrollment target
NCT07652658 is a Phase 2 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 359 participants.
The verdict
NCT07652658, a Phase 2 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 359 participants
- Enrollment target
Study Summary
This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.
Interventions
- OTHER Placebo for AZD8965
- DRUG AZD8965 low dose
- DRUG AZD8965 medium dose
- DRUG AZD8965 high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2026-06-11 |
| Est. Completion | 2028-09-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07652658
The ClinicalTrials.gov registry entry for NCT07652658 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 359 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo for AZD8965 is the first listed.
NCT07652658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07652658 about?
NCT07652658 is a clinical study titled "A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.". This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic...
What is the current status of trial NCT07652658?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 359 participants. The study started on 2026-06-11. Estimated completion is 2028-09-14.
What interventions are being tested in trial NCT07652658?
The interventions under investigation include: Placebo for AZD8965 (OTHER), AZD8965 low dose (DRUG), AZD8965 medium dose (DRUG), AZD8965 high dose (DRUG).
Who is sponsoring clinical trial NCT07652658?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.